FDA issues first warning letter to compounding pharmacy over drug copies

The FDA has issued its first warning letter to a compounding pharmacy for allegedly violating the legal prohibition against compounding "essentially a copy" of an FDA-approved, commercially available drug, mondaq.com reported. This letter, dated September 18, 2026, was based on evidence collected during a November 2025 FDA inspection and included allegations related to drug product adulteration.

The warning letter follows recent rulings by the Fifth Circuit US Court of Appeals that upheld the FDA's efforts to reduce national drug shortages for injectable tirzepatide and semaglutide products, mondaq.com explained. The FDA requires that when a compounded version of an FDA-approved drug is needed, the prescriber must document the clinical difference that the compounded drug provides for the patient in the written order.

The FDA's Office of Compounding Quality and Compliance emphasized that generating prescriptions that undermine the individualized nature of compounded drugs is problematic, mondaq.com noted. The agency's findings suggest that the practices cited in the warning letter may not be isolated to a single pharmacy, potentially marking the start of a broader enforcement sweep.

This development is significant for compounding pharmacies, telehealth platforms working with compounders, and investors in such businesses, mondaq.com added. The FDA's actions indicate increased scrutiny of compounding practices that replicate commercially available drugs without clear clinical justification.